Hyperbaric Oxygen Therapy for Threatened Nipple-Sparing Mastectomy Flaps: An Adjunct for Flap Salvage.
Journal
Annals of plastic surgery
ISSN: 1536-3708
Titre abrégé: Ann Plast Surg
Pays: United States
ID NLM: 7805336
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
medline:
18
5
2023
pubmed:
14
3
2023
entrez:
13
3
2023
Statut:
ppublish
Résumé
Nipple-sparing mastectomy (NSM) is emerging as the standard of care for treatment of breast cancer because of its oncologic safety and superior aesthetic outcomes. However, ischemia or necrosis of the skin flap and/or nipple-areola complex remain frequent complications. Hyperbaric oxygen therapy (HBOT) has emerged as a potential adjunct for flap salvage, although it is not currently a widely accepted practice. Here we review our institution's experience using a protocol of HBOT in patients with signs of flap ischemia or necrosis after NSM. Retrospective review identified all patients treated with HBOT at our institution's hyperbaric and wound care center because of signs of ischemia after NSM. Treatment parameters consisted of 90-minute dives at 2.0 atmosphere once or twice daily. Patients unable to tolerate dives were considered a treatment failure, whereas those lost to follow-up were excluded from analysis. Patient demographics, surgical characteristics, and treatment indications were recorded. Primary outcomes assessed were flap salvage (no operative revision), need for revision procedures, and treatment complications. A total of 17 patients and 25 breasts met the inclusion criteria. The mean ± SD time to initiation of HBOT was 9.47 ± 12.7 days. The mean ± SD age was 46.7 ± 10.4 years, and mean ± SD follow-up time was 36.5 ± 25.6 days. Indications for NSM included invasive cancer (41.2%), carcinoma in situ (29.4%), and breast cancer prophylaxis (29.4%). Initial reconstruction included tissue-expander placement (47.1%), autologous reconstruction with deep inferior epigastric flaps (29.4%), and direct-to-implant reconstruction (23.5%). Hyperbaric oxygen therapy indications included ischemia or venous congestion for 15 breasts (60.0%) and partial thickness necrosis for 10 breasts (40.0%). Flap salvage was achieved in 22 of 25 breasts (88.0%). Reoperation was required for 3 breasts (12.0%). Hyperbaric oxygen therapy-related complications were observed in 4 patients (23.5%), which included 3 patients with mild ear pain and 1 patient with severe sinus pressure leading to treatment abortion. Nipple-sparing mastectomy is an invaluable tool for breast and plastic surgeons to achieve oncologic and cosmetic goals. However, ischemia or necrosis of the nipple-areola complex or mastectomy skin flap remains frequent complications. Hyperbaric oxygen therapy has emerged as a possible intervention for threatened flaps. Our results demonstrate the utility of HBOT in this population to achieve excellent NSM flap salvage rates.
Sections du résumé
BACKGROUND
Nipple-sparing mastectomy (NSM) is emerging as the standard of care for treatment of breast cancer because of its oncologic safety and superior aesthetic outcomes. However, ischemia or necrosis of the skin flap and/or nipple-areola complex remain frequent complications. Hyperbaric oxygen therapy (HBOT) has emerged as a potential adjunct for flap salvage, although it is not currently a widely accepted practice. Here we review our institution's experience using a protocol of HBOT in patients with signs of flap ischemia or necrosis after NSM.
METHODS
Retrospective review identified all patients treated with HBOT at our institution's hyperbaric and wound care center because of signs of ischemia after NSM. Treatment parameters consisted of 90-minute dives at 2.0 atmosphere once or twice daily. Patients unable to tolerate dives were considered a treatment failure, whereas those lost to follow-up were excluded from analysis. Patient demographics, surgical characteristics, and treatment indications were recorded. Primary outcomes assessed were flap salvage (no operative revision), need for revision procedures, and treatment complications.
RESULTS
A total of 17 patients and 25 breasts met the inclusion criteria. The mean ± SD time to initiation of HBOT was 9.47 ± 12.7 days. The mean ± SD age was 46.7 ± 10.4 years, and mean ± SD follow-up time was 36.5 ± 25.6 days. Indications for NSM included invasive cancer (41.2%), carcinoma in situ (29.4%), and breast cancer prophylaxis (29.4%). Initial reconstruction included tissue-expander placement (47.1%), autologous reconstruction with deep inferior epigastric flaps (29.4%), and direct-to-implant reconstruction (23.5%). Hyperbaric oxygen therapy indications included ischemia or venous congestion for 15 breasts (60.0%) and partial thickness necrosis for 10 breasts (40.0%). Flap salvage was achieved in 22 of 25 breasts (88.0%). Reoperation was required for 3 breasts (12.0%). Hyperbaric oxygen therapy-related complications were observed in 4 patients (23.5%), which included 3 patients with mild ear pain and 1 patient with severe sinus pressure leading to treatment abortion.
CONCLUSIONS
Nipple-sparing mastectomy is an invaluable tool for breast and plastic surgeons to achieve oncologic and cosmetic goals. However, ischemia or necrosis of the nipple-areola complex or mastectomy skin flap remains frequent complications. Hyperbaric oxygen therapy has emerged as a possible intervention for threatened flaps. Our results demonstrate the utility of HBOT in this population to achieve excellent NSM flap salvage rates.
Identifiants
pubmed: 36913565
doi: 10.1097/SAP.0000000000003441
pii: 00000637-202305002-00004
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
S125-S129Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Alvin C, Kwok CJP, Chung KC. Grabb and Smith's Plastic Surgery . 8th ed. Philadelphia, PA: Wolters Kluwer Health, Inc.; 2020:583–597.
Ou KW, Yu JC, Ho MH, et al. Oncological safety and outcomes of nipple-sparing mastectomy with breast reconstruction: a single-centered experience in Taiwan. Ann Plast Surg . 2015;74(Suppl 2):S127–S131.
Wu ZY, Kim HJ, Lee J, et al. Oncologic safety of nipple-sparing mastectomy in patients with breast cancer and tumor-to-nipple distance </= 1 cm: a matched cohort study. Ann Surg Oncol . 2021;28:4284–4291.
Yamashita Y, Tsunoda H, Nagura N, et al. Long-term oncologic safety of nipple-sparing mastectomy with immediate reconstruction. Clin Breast Cancer . 2021;21:352–359.
Tousimis E, Haslinger M. Overview of indications for nipple sparing mastectomy. Gland Surg . 2018;7:288–300.
Bocian A, Kedzierawski P, Kurczych K, et al. Nipple-sparing mastectomy with immediate breast reconstruction — early complications and outcomes of the treatment. Prz Menopauzalny . 2020;19:117–122.
Razavi SA, Hart AL, Carlson GW. Ischemic complications after bilateral nipple-sparing mastectomy and implant-based reconstruction: a critical analysis. Ann Plast Surg . 2021;86(6S Suppl 5):S526–S531.
Salibian AA, Frey JD, Bekisz JM, et al. Ischemic complications after nipple-sparing mastectomy: predictors of reconstructive failure in implant-based reconstruction and implications for decision-making. Plast Reconstr Surg Glob Open . 2019;7:e2280.
Young WA, Degnim AC, Hoskin TL, et al. Outcomes of >1300 nipple-sparing mastectomies with immediate reconstruction: the impact of expanding indications on complications. Ann Surg Oncol . 2019;26:3115–3123.
Alperovich M, Harmaty M, Chiu ES. Treatment of nipple-sparing mastectomy necrosis using hyperbaric oxygen therapy. Plast Reconstr Surg . 2015;135:1071e–1072e.
Lotfi P, Dayan J, Chiu ES, et al. Hyperbaric oxygen therapy and mastectomy flap ischemia following nipple-sparing mastectomy and immediate breast reconstruction. Plast Reconstr Surg . 2020;145:1114e–1115e.
Shuck J, O'Kelly N, Endara M, et al. A critical look at the effect of hyperbaric oxygen on the ischemic nipple following nipple sparing mastectomy and implant based reconstruction: a case series. Gland Surg . 2017;6:659–665.
Moon RE. Undersea & Hyperbaric Medical Society. 2019;14: ed. Metabolic and Undersea Society, Available at: https://www.uhms.org/ . Accessed February 1, 2022.
Thom SR. Hyperbaric oxygen: its mechanisms and efficacy. Plast Reconstr Surg Jan 2011;127 Suppl 1:131S–141S.
Valero MG, Muhsen S, Moo TA, et al. Increase in utilization of nipple-sparing mastectomy for breast cancer: indications, complications, and oncologic outcomes. Ann Surg Oncol . 2020;27:344–351.
Athamnah M, Rabai NA, Shkoukani ZW, et al. Nipple-sparing mastectomy: initial experience evaluating patients satisfaction and oncological safety in a tertiary care centre in Jordan. Cureus . 2021;13:e19238.
Francis EC, Dimovska EOF, Chou HH, et al. Nipple-sparing mastectomy with immediate breast reconstruction with a deep inferior epigastric perforator flap without skin paddle using delayed primary retention suture. J Surg Oncol . 2022;125:1202–1210.
Chatterjee A, Nahabedian MY, Gabriel A, et al. Early assessment of post-surgical outcomes with pre-pectoral breast reconstruction: a literature review and meta-analysis. J Surg Oncol . 2018;117:1119–1130.
Thangarajah F, Treeter T, Krug B, et al. Comparison of subpectoral versus prepectoral immediate implant reconstruction after skin- and nipple-sparing mastectomy in breast cancer patients: a retrospective hospital-based cohort study. Breast Care (Basel) . 2019;14:382–387.
Braun SE, Dreicer M, Butterworth JA, et al. Do nipple necrosis rates differ in prepectoral versus submuscular implant-based reconstruction after nipple-sparing mastectomy? Ann Surg Oncol . 2020;27:4760–4766.
Moen I, Stuhr LE. Hyperbaric oxygen therapy and cancer—a review. Target Oncol . 2012;7:233–242.
Spruijt NE, Hoekstra LT, Wilmink J, et al. Hyperbaric oxygen treatment for mastectomy flap ischaemia: a case series of 50 breasts. Diving Hyperb Med . 2021;51:2–9.
Li K, Zhang Z, Nicoli F, et al. Application of indocyanine green in flap surgery: a systematic review. J Reconstr Microsurg . 2018;34:77–86.
Francis A, Baynosa RC. Hyperbaric oxygen therapy for the compromised graft or flap. Adv Wound Care (New Rochelle) . 2017;6:23–32.